Suchergebnisse - "Muser, Erik"

PubPharm (57)

1

Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States

enthalten in: Journal of medical economics | 2024

von Kaye, D. | Khilfeh, I. | Muser, E. | +5

UpdateIn: J Med Econ. 2024 Jan-Dec;27(1):605. - PMID 38607231

2

Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation

enthalten in: Journal of medical economics | 2024

von Kaye, D. | Khilfeh, I. | Muser, E. | +6

UpdateIn: J Med Econ. 2024 Jan-Dec;27(1):518. - PMID 38564340

3

Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate : A retrospective cohort study

enthalten in: Urologic oncology | 2023

von Lowentritt, B. | Pilon, D. | Waters, D. | +9

4

Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer : A comparison of patients initiated on apalutamide or enzalutamide

enthalten in: Urologic oncology | 2023

von Lowentritt, B. | Pilon, D. | Khilfeh, I. | +7

5

Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab

enthalten in: Current medical research and opinion | 2023

von Zhdanava, M. | Ding, Z. | Manceur, A. | +5

6

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease : Results From the SUCCESS Consortium

enthalten in: The American journal of gastroenterology | 2023

von Johnson, A. | Barsky, M. | Ahmed, W. | +48

7

Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics : a pooled study of three United States claim databases

enthalten in: Current medical research and opinion | 2022

von Sah, J. | Teeple, A. | Muser, E. | +2

8

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn's Disease or Ulcerative Colitis in the United States

enthalten in: Crohn's & colitis 360 | 2022

von Ding, Z. | Muser, E. | Izanec, J. | +3

9

Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional Agents

enthalten in: Crohn's & colitis 360 | 2022

von Pilon, D. | Ding, Z. | Muser, E. | +4

10

Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USA

enthalten in: Drugs - real world outcomes | 2021

von Ding, Z. | Obando, C. | Muser, E. | +2

1
2
3
4
5
6
Nächster »
[6]